Webcisplatin) Nadir platelets <50,000 /mm 3 regardless of nadir ANC 75 % of previous dose (both ALIMTA and cisplatin) Nadir platelets <50,000/mm 3 with bleeding a, regardless of nadir ANC 50% of previous dose (both ALIMTA and cisplatin) a These criteria meet the National Cancer Institute Common Toxicity Criteria (CTC v2.0; NCI WebThe recommended dose of Pemetrexed for Injection when administered with cisplatin in patients with a creatinine clearance (calculated by Cockcroft-Gault equation) of 45 mL/min or greater is 500 mg/m 2 as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity. 2.3 Renal Impairment
Cisplatin Injection (For Intravenous Use) - DailyMed
WebCisplatin is a chemotherapy drug that contains the metal platinum. It stops or slows growth of cancer cells and other cells that grow rapidly by damaging their DNA. FDA Approved Yes FDA label information for this drug is available at DailyMed. Use in Cancer Cisplatin is approved to be used alone or with other drugs to treat: Bladder cancer. WebJan 3, 2024 · DailyMed - DEXAMETHASONE tablet Label: DEXAMETHASONE tablet NDC Code (s): 55154-4901-0, 55154-4914-0 Packager: Cardinal Health 107, LLC This is a repackaged label. Source NDC Code (s): 0054-8175, 0054-8176 Category: HUMAN PRESCRIPTION DRUG LABEL DEA Schedule: None Marketing Status: Abbreviated … flork historico
DailyMed - ETOPOSIDE injection
WebNov 2, 2024 · Cisplatin 20,21,j. Day 1: Cisplatin 50mg/m 2 IV over 1 hour. Repeat cycle every 3 weeks. Cisplatin/Doxorubicin 20,22-24,j,k. Day 1: Doxorubicin 60mg/m 2 IV push. Day 1: Cisplatin 50mg/m 2 over 1 hour. WebCisplatin is a platinum-based agent whose nephrotoxicity is thought related to the chloride in the cis position. Cisplatin gains entry into tubular cells via uptake by the OCT-2 … WebDailyMed - FUROSEMIDE tablet Label: FUROSEMIDE tablet NDC Code (s): 43063-849-21, 43063-849-30, 43063-849-60, 43063-849-90 Packager: PD-Rx Pharmaceuticals, Inc. This is a repackaged label. Source NDC Code (s): 43547-401 Category: HUMAN PRESCRIPTION DRUG LABEL DEA Schedule: None Marketing Status: Abbreviated New Drug Application greece rulers and emperors